文献速递浆细胞疾病

临床疑似管型肾病:一项回顾性、全国性真实世界研究

Clinically-suspected cast nephropathy: A retrospective, national, real-world study.
PubMed 文献 · Am J Hematol · 2020-08-26

基于丹麦多发性骨髓瘤登记处(DMMR)2013至2017年诊断的2252例患者,识别出204例临床疑似管型肾病(CN)患者,定义为诊断时血清肌酐>177 μmol/L且血清游离轻链>1000 mg/L。尽管94%患者及时接受硼替佐米为基础治疗,33%在诊断后第一年死亡,肾脏恢复与受累血清游离轻链深度下降相关。

要点

  • 临床疑似CN定义:诊断时血清肌酐>177 μmol/L且血清游离轻链>1000 mg/L。
  • 31%患者表现为透析依赖的肾衰竭,19%行肾活检,其中74%显示CN。
  • 尽管94%接受硼替佐米为基础治疗,33%在诊断后第一年死亡。

核心结论

  • 当前标准治疗下,表现为临床疑似CN的多发性骨髓瘤患者一年死亡率高得惊人。
  • 早期且深度的血液学缓解对生存至关重要。

研究设计与样本

  • 回顾性、全国性真实世界研究,基于丹麦多发性骨髓瘤登记处(DMMR)。
  • 纳入2013至2017年诊断的2252例患者,识别出204例临床疑似CN患者。
  • 临床疑似CN定义为诊断时血清肌酐>177 μmol/L且血清游离轻链>1000 mg/L。

主要发现

  • 204例临床疑似CN患者中位年龄72岁,31%表现为透析依赖的肾衰竭。
  • 19%患者行肾活检,其中74%显示CN。
  • 94%患者及时启动硼替佐米为基础治疗,33%在诊断后第一年死亡。
  • 与DMMR中其他有症状多发性骨髓瘤患者相比,临床疑似CN患者无论移植资格如何,总生存期更差。
  • 肾脏恢复与受累血清游离轻链深度下降相关;一线治疗达到非常好的部分缓解或更好和/或治疗开始后3个月时受累血清游离轻链深度下降与更优总生存期相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Presentation with severe acute kidney injury due to cast nephropathy (CN) is a medical emergency in multiple myeloma (MM), with high risk of dialysis-dependent renal failure and death. Accrual of patients with CN into interventional studies is difficult, while phase III trials exclude patients with severe renal insufficiency. Real-world data are warranted. We assessed 2252 patients from the population-based Danish Multiple Myeloma Registry (DMMR) who were diagnosed between 2013 and 2017. We identified 204 patients with clinically-suspected CN, defined as serum creatinine concentration >177 μmol/L and serum free light chain (sFLC) concentration >1000 mg/L at the time of diagnosis. The median age was 72 years. Thirty-one percent of patients presented with dialysis-dependent renal failure. Kidney biopsies were performed in 19% of patients and showed CN in 74% of cases. Despite prompt initiation of bortezomib-based therapy in 94% of patients, 33% of patients died in the first year after diagnosis. Compared with the rest of the patients in the DMMR with symptomatic MM, patients with clinically-suspected CN had worse overall survival (OS) irrespective of transplant eligibility. Achievement of renal recovery was associated with deep reductions of involved sFLC. Achievement of very good partial response or better in the first line of therapy and/or deep reduction of involved sFLC at 3 months after initiation of therapy were associated with superior OS. In conclusion, MM patients presenting with clinically-suspected CN have an alarmingly high one-year mortality when treated with current standards of care. Early and deep hematologic response is crucial for survival.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Szabo AG, Thorsen J, Iversen KF, et al. Clinically-suspected cast nephropathy: A retrospective, national, real-world study. Am J Hematol. 2020. PMID: 32777108. doi:10.1002/ajh.25959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。